Archive: 02/05/2016

Mepolizumab in severe asthma: Added benefit not proven

The monoclonal antibody mepolizumab has been approved since the end of 2015 for the treatment of adults with severe refractory eosinophilic asthma. The German Institute for Quality and Efficiency in Health Care (IQWiG) now ...

page 7 from 9